Inhibition of thrombin-activated fibrinolysis inhibitor increases survival in experimental kidney fibrosis

Journal of the American Society of Nephrology

Volumn 26, Issue 8, 2015, Pages 1925-1937

  Atkinson, John M ^a,b   Pullen, Nick ^c   Da Silva Lodge, Michelle ^a   Williams, Lynne ^a   Johnson, Tim S ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UCB PHARMA   (Belgium)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; CREATININE; FIBRONECTIN; KIDNEY INJURY MOLECULE 1; LAMININ; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLASMIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UK 396082; UNCLASSIFIED DRUG; 5-AMINO-2-((1-N-PROPYL-1H-IMIDAZOL-4-YL)METHYL)PENTANOIC ACID; AMINO ACID; BIOLOGICAL MARKER; IMIDAZOLE DERIVATIVE;

ADULT; AFRICAN CARIBBEAN; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUCASIAN; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; EXPERIMENTAL RENAL FIBROSIS; FEMALE; HUMAN; IN VITRO STUDY; KIDNEY FUNCTION; MALE; NONHUMAN; PAKISTANI; PRIORITY JOURNAL; PROTEINURIA; RAT; UREA NITROGEN BLOOD LEVEL; VEIN THROMBOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; KIDNEY; KIDNEY FUNCTION TEST; METABOLISM; MIDDLE AGED; MORTALITY; NEPHRECTOMY; PATHOLOGY; PRECLINICAL STUDY; RANDOMIZATION; RENAL INSUFFICIENCY, CHRONIC; URINE; WISTAR RAT;

ADULT; AGED; AMINO ACIDS; ANIMALS; BIOMARKERS; CARBOXYPEPTIDASE B2; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; FIBRINOLYSIN; FIBROSIS; HUMANS; IMIDAZOLES; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NEPHRECTOMY; RANDOM ALLOCATION; RATS, WISTAR; RENAL INSUFFICIENCY, CHRONIC;

EID: 84938906171     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014030303     Document Type: Article

References (59)

1. Risdon RA, SJ, de Vardener HE: Relationship between renal function and histologic changes found in renal-biopsy specimens from patients with persistent glomerulonephritis. Lancet 2: 363-366, 1968
2. Schainuck LI, Striker GE, Cutler RE, Benditt EP: Structural-functional correlations in renal disease. II. The correlations. Hum Pathol 1: 631-641, 1970
3. Sharma AK, Mauer SM, Kim Y, Michael AF: Interstitial fibrosis in obstructive nephropathy. Kidney Int 44: 774-788, 1993
4. Bohle A, Mackensenhaen S, Gise H, Grund KE, Wehrmann M, Batz C, Bogenschutz O, Schmitt H, Nagy J, Muller C, Muller G: The consequences of tubulointerstitial changes for renal-function in glomerulopathies-a morphometric and cytological analysis. Dev Nephrol 31: 29-39, 1991
5. Fogel MA, Boyd CD, Leardkamolkarn V, Abrahamson DR, Minto AWM, Salant DJ: Glomerular basement membrane expansion in passive Heymann nephritis. Absence of increased synthesis of type IV collagen, laminin, or fibronectin. Am J Pathol 138: 465-475, 1991
6. Merritt SE, Killen PD, Phan SH, Wiggins RC: Analysis of alpha 1 (I) procollagen alpha 1 (IV) collagen, and beta-actin mRNA in glomerulus and cortex of rabbits with experimental anti-glomerular basement membrane disease. Evidence for early extraglomerular collagen biosynthesis. Lab Invest 63: 762-769, 1990
7. Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 45: 916-927, 1994
8. Kaneto H, Morrissey J, Klahr S: Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 44: 313-321, 1993
9. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Böttinger EP, Klotman PE, Thorgeirsson SS: Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 74: 991-1003, 1996
10. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53: 853-861, 1998
11. Yokoi H, Sugawara A, Mukoyama M, Mori K, Makino H, Suganami T, Nagae T, Yahata K, Fujinaga Y, Tanaka I, Nakao K: Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: A potential target for preventing renal fibrosis. Am J Kidney Dis 38[Suppl 1]: S134-S138, 2001
12. Johnson TS, El-Koraie AF, Skill NJ, Baddour NM, El Nahas AM, Njloma M, Adam AG, Griffin M: Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 14: 2052-2062, 2003
13. Johnson TS, Griffin M, Thomas GL, Skill J, Cox A, Yang B, Nicholas B, Birckbichler PJ, Muchaneta-Kubara C, Meguid El Nahas A: The role of transglutaminase in the rat subtotal nephrectomy model of renal fi-brosis. J Clin Invest 99: 2950-2960, 1997
14. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A: Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51: 164-172, 1997
15. Oda T, Jung YO, Kim HS, Cai X, López-Guisa JM, Ikeda Y, Eddy AA: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60: 587-596, 2001
16. Sharma S, Farrington K, Kozarski R, Christopoulos C, Niespialowska-Steuden M, Moffat D, Gorog DA: Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. Eur Heart J 34: 354-363, 2013
17. Undas A, Nycz K, Pastuszczak M, Stompor T, Zmudka K: The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome. Blood Coagul Fibrinolysis 21: 522-527, 2010
18. Shirakawa J, Togashi Y, Tajima K, Orime K, Kikuchi K, Miyazaki T, Sato K, Kimura M, Goshima Y, Terauchi Y: Plasminogen activator inhibitor-1 is associated with renal dysfunction independent of BMI and serum lipid levels in patients with type 2 diabetes. Diabetes Res Clin Pract 97: e9-e12, 2012
19. Sörensen-Zender I, Rong S, Susnik N, Lange J, Gueler F, Degen JL, Melk A, Haller H, Schmitt R: Role of fibrinogen in acute ischemic kidney injury. Am J Physiol Renal Physiol 305: F777-F785, 2013
20. Hoffmann D, Bijol V, Krishnamoorthy A, Gonzalez VR, Frendl G, Zhang Q, Goering PL, Brown RP, Waikar SS, Vaidya VS: Fibrinogenexcretionin the urine and immunoreactivity in the kidney serves as a translational biomarker for acute kidney injury. Am J Pathol 181: 818-828, 2012
21. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, Nejak K, Liu Y: Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 110: 1525-1538, 2002
22. Zhang G, Kim H, Cai X, López-Guisa JM, Alpers CE, Liu Y, Carmeliet P, Eddy AA: Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol 14: 1254-1271, 2003
23. Bruno NE, Yano Y, Takei Y, Gabazza EC, Qin L, Nagashima M, Morser J, D'Alessandro-Gabazza CN, Taguchi O, Sumida Y: Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitialfibrosis. J Thromb Haemost 6: 139-146, 2008
24. Bruno NE, Yano Y, Takei Y, Qin L, Suzuki T, Morser J, D'Alessandro-Gabazza CN, Mizoguchi A, Suzuki K, Taguchi O, Gabazza EC, Sumida Y: Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatablefibrinolysis inhibitor deficiency. Thromb Haemost 100: 90-100, 2008
25. Atkinson JM, Pullen N, Johnson TS: An inhibitor of thrombin activated fibrinolysis inhibitor (TAFI) can reduceextracellularmatrix accumulation in an in vitro model of glucose induced ECM expansion. Matrix Biol 32: 277-287, 2013
26. Lijnen HR: Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86: 324-333, 2001
27. Vassalli JD, Sappino AP, Belin D: The plasminogen activator/plasmin system. J Clin Invest 88: 1067-1072, 1991
28. Bochenek M, Zalewski J, Sadowski J, Undas A: Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease. J Thromb Thrombolysis 35: 264-270, 2013
29. Ajay AK, Saikumar J, Bijol V, Vaidya VS: Heterozygosity for fibrinogen resultsin efficientresolutionofkidney ischemiareperfusion injury. PLoS ONE 7: e45628, 2012
30. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 270: 14477-14484, 1995
31. Nesheim M: Thrombin and fibrinolysis. Chest 124[Suppl]: 33S-39S, 2003
32. Bunnage ME, Blagg J, Steele J, Owen DR, Allerton C, McElroy AB, Miller D, Ringer T, Butcher K, Beaumont K, Evans K, Gray AJ, Holland SJ, Feeder N, Moore RS, Brown DG: Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. J Med Chem 50: 6095-6103, 2007
33. Matsuo S, López-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, Peters MA, Zhang G, Eddy AA: Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 67: 2221-2238, 2005
34. Yamaguchi I, Lopez-Guisa JM, Cai X, Collins SJ, Okamura DM, Eddy AA: Endogenousurokinaselacks antifibrotic activity during progressive renal injury. Am J Physiol Renal Physiol 293: F12-F19, 2007
35. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ Jr, Fay WP, Morser J: Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 109: 101-110, 2002
36. Oldroyd SD, Thomas GL, Gabbiani G, El Nahas AM: Interferon-gamma inhibits experimental renal fibrosis. Kidney Int 56: 2116-2127, 1999
37. Haylor J, Dencausse A, Vickers M, Nutter F, Jestin G, Slater D, Idee JM, Morcos S: Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol 45: 507-512, 2010
38. Johnson TS, Haylor JL, Thomas GL, Fisher M, El Nahas AM: Matrix metalloproteinases and their inhibitions in experimental renal scarring. Exp Nephrol 10: 182-195, 2002
39. Da Silva M, El Nahas M, Johnson TS: Urinary transglutaminase 2 (TG2) as a potential biomarker of chronic kidney disease detection and progression. Lancet 381: S33, 2013
40. Da Silva-Lodge M, El Nahas M, Johnson T: Urinary -g (glutamyl) lysine: a novel biomarker of chronic kidney disease. Presented at the British Renal Society/Renal Association Conference, Manchester, United Kingdom, May 17-20, 2010
41. Hansson J, Vasan RS, Ärnlöv J, Ingelsson E, Lind L, Larsson A, Michaëlsson K, Sundström J: Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study. PLoS ONE 6: e16185, 2011
42. Liu BC, Zhang L, Lv LL, Wang YL, Liu DG, Zhang XL: Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease. Am J Nephrol 26: 483-490, 2006
43. Hoffmann D, Adler M, Vaidya VS, Rached E, Mulrane L, Gallagher WM, Callanan JJ, Gautier JC, Matheis K, Staedtler F, Dieterle F, Brandenburg A, Sposny A, Hewitt P, Ellinger-Ziegelbauer H, Bonventre JV, Dekant W, Mally A: Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicol Sci 116: 8-22, 2010
44. Zheng M, Lv LL, Cao YH, Liu H, Ni J, Dai HY, Liu D, Lei XD, Liu BC: A pilot trial assessing urinary gene expression profiling with an mRNA array for diabetic nephropathy. PLoS ONE 7: e34824, 2012
45. Basu R, Lee J, Wang Z, Patel VB, Fan D, Das SK, Liu GC, John R, Scholey JW, Oudit GY, Kassiri Z: Loss of TIMP3 selectively exacerbates diabetic nephropathy. Am J Physiol Renal Physiol 303: F1341-F1352, 2012
46. Kassiri Z, Oudit GY, Kandalam V, Awad A, Wang X, Ziou X, Maeda N, Herzenberg AM, Scholey JW: Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol 20: 1223-1235, 2009
47. Anderson S, Meyer TW, Rennke HG, Brenner BM: Controlof glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612-619, 1985
48. Simons JL, Provoost AP, Anderson S, Rennke HG, Troy JL, Brenner BM: Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury. Kidney Int 46: 396-404, 1994
49. Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, Ehmke H, Rump LC, Ritz E: Glomerulosclerosis and progression: Effect of sub-antihypertensive doses of alpha and beta blockers. Kidney Int 60: 1309-1323, 2001
50. Nabokov AV, Amann K, Wessels S, Münter K, Wagner J, Ritz E: Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int 55: 512-519, 1999
51. Haraguchi M, Border WA, Huang Y, Noble NA: t-PA promotes glo-merular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int 59: 2146-2155, 2001
52. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951
53. Huang L, Scarpellini A, Funck M, Verderio EA, Johnson TS: Development of a chronic kidney disease model in C57BL/6 mice with relevance to human pathology. Nephron Extra 3: 12-29, 2013
54. Wong TYH, Poon P, Szeto CC, Chan JCN, Li PKT: Association of plas-minogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int 57: 632-638, 2000
55. Mishra J, Ma Q, Kelly C, Mitsnefes M, Mori K, Barasch J, Devarajan P: Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol 21: 856-863, 2006
56. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, Buemi M: Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 52: 595-605, 2008
57. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M: Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273: 4135-4142, 1998
58. Liu Y: Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217, 2006
59. Vleming LJ, Baelde JJ, Westendorp RGJ, Daha MR, van Es LA, Bruijn JA: Progression of chronic renal disease in humans is associated with the deposition of basement membrane components and decorin in the interstitial extracellular matrix. Clin Nephrol 44: 211-219, 1995